Access to Oncology Medicines Coalition
A UICC-led initiative pioneering access solutions for cancer medicines
The Access to Oncology Medicines Coalition (ATOM Coalition) is a global initiative, led by the Union for International Cancer Control (UICC), in collaboration with over 40 partners across the private and civil society sectors. It aims to address the barriers to availability, affordability and appropriate use of oncology medicines in low- and lower-middle income countries (LLMICs).
The ATOM Coalition ambition
“To reduce suffering and deaths caused by cancer in low- and lower-middle income countries through improved access to and use of essential cancer medicines.”
News and Resources
Latest news
15 December 2025 – Shaping the next phase of the ATOM Coalition
The new Executive Director of the Access to Oncology Medicines (ATOM) Coalition, Natasha Shah, outlines the work ahead to expand access to cancer care in low- and lower-middle-income countries through local partnerships, capacity-strengthening and effective pathways to innovative medicines.
Latest blog
11 December 2025 – Bridging the divide: financing cancer care to achieve true universal health coverage
Marking Universal Health Coverage (UHC) Day on 12 December, Sarbani of the UICC-led Access to Oncology Medicines (ATOM) Coalition writes about how innovative health financing strategies could transform access and equity under UHC in LMICs that face critical gaps in cancer care financing.
Three areas of focus
Building on UICC’s long-standing advocacy for the global availability of cancer medicines, the ATOM Coalition is dedicated to identifying and developing access solutions that address key barriers and have the potential to make substantial impact on global efforts to increase access to essential oncology medicines and improve health systems in LLMICs.
Harnessing collective expertise
Guided by the insights of international experts from the UICC global cancer community, the ATOM Coalition Expert Advisory Groups (EAGs) offer invaluable counsel, expertise and recommendations on key issues that impact access to prioritised essential cancer medicines and diagnostics in LLMICs and ATOM Coalition target countries.